ADx logo


Koen Dewaele, CEO

Koen Dewaele, MSc Biology, has more than 25 years experience in the diagnostic industry. He joined the Innogenetics marketing team in 1999 as a product manager. He has held several positions since then but could excel most when leading the Alzheimer program in 2004 – 2006 and in 2010. He has a good understanding of both the business and the science which helps to define the best strategy. Besides he is an organizer and people manager. Before joining Innogenetics, Koen has held M&S positions in several other IVD companies (Akzo, Baxter, Sigma Aldrich). In 2008, he organized – together with Flanders Bio- and presided a successfully attended seminar on companion diagnostics.

Paul Appermont, Chairman & Chief Business Officer

Paul J. Appermont, Dr. Jur. MBA, started his career in 1972 as an international Business Lawyer at Janssen Pharma/J&J. He served as VP Trade & Licensing for Biogen S.A. (Geneva) from 1981 until 1985.He joined Innogenetics in 1987 as Executive Consultant responsible for Business Development focused on Alzheimer's disease and on business in the Far East, in particular in China. His first contacts with China date back to 1979 as a pioneer of the Janssen Pharma Joint Venture in Xi'an. He also served in the past as a consultant to a number of innovative companies, including Sorin Biomedica and as President of the Benelux Licensing Executives Society. He was President of the Belgian Bioindustries Association and Board member of EuropaBio. Dr. Appermont studied at the Universities of Leuven and Geneva and has 38 years of experience in the pharmaceutical and biotech industry. He's a dealmaker & networker, 'From Contact to Contract'. Paul is also the founder and President of ChinArt, specialised in 'objets d'art' and in consultancy work.

Eugeen Vanmechelen, Chief Scientific Officer

Eugeen Vanmechelen , PhD in Molecular Biology, graduated from the University of Ghent (Prof. W. Fiers) and joined Innogenetics in 1987 where he built up the AD diagnostic business since 1993. He is (co-)inventor of more than 10 patents and has been an invited speaker on several national and international congresses. He is the author of more than 80 peer-review publications.

Hugo Vanderstichele, Chief Integration Officer

Hugo Vanderstichele , PhD in Molecular Biology, graduated from the University of Ghent and joined Innogenetics in 1989 where he - while working for the AD program - built a WW acknowledged developmental expertise. He is one of the main drivers within the international AD biomarker consortia. He is the author of more than 80 peer-review publications. He is (co-)inventor of more than 10 patents.